Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by FBORBUSTon Oct 09, 2020 3:07pm
255 Views
Post# 31696799

New Levels of Underwhelming

New Levels of Underwhelming Wow

I'm trying to decide what's more underwhelming in this latest news release, the cancelation of the SK trials (probably should have happened 2 months ago) or Dr. Mark Swaims credentials (bio pub flounderer) - great more Algernon glad handing with the people they know and love.

Take some of the money spent on promotion and show investors the process patents . . . are they filed? How is that coming along, It's hard to take this stock serious with the constant rinky dinky promotional crud. Trial results might mean something but Algernon has put nothing up to show that they will own the results. Please show us the patents or explain how it is going.  

Hey I'm excited about the repurposing but  (and congrats on the insight there) but they can't expect to hand it off to some sugar daddy with out doing a little more work and creating some value. All the promotional gigs have shown zero value creation.

It's time to start building and investing in a real company, but it seems to not even on the to do list.  


<< Previous
Bullboard Posts
Next >>